Oral paricalcitol (19-nor-1,25- Dihydroxyvitamin D2) in women receiving chemotherapy for metastatic breast cancer:A feasibility trial

Cancer Biology and Therapy

Volumn 14, Issue 6, 2013, Pages 476-480

  Lawrence, Julia A ^a   Akman, Steven A ^b   Melin, Susan A ^a   Case, L Douglas ^a   Schwartz, Gary G ^a  

^a WAKE FOREST BAPTIST HEALTH   (United States)

^b Roper St Francis Health Care   (United States)

Author keywords

Cancer treatment; Metastatic breast cancer; Paricalcitol; Vitamin D

Indexed keywords

25 HYDROXYVITAMIN D; BEVACIZUMAB; CALCIUM; IXABEPILONE; PARATHYROID HORMONE; PARICALCITOL; ANTINEOPLASTIC AGENT; ERGOCALCIFEROL; TAXOID;

ADULT; AGED; ARTICLE; BREAST METASTASIS; CALCIUM BLOOD LEVEL; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; DRUG ACTIVITY; DRUG DOSE ESCALATION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; PARATHYROID HORMONE BLOOD LEVEL; BREAST NEOPLASMS; CHEMICALLY INDUCED; CLINICAL TRIAL; DOSE RESPONSE; FEASIBILITY STUDY; HYPERCALCEMIA; LYMPH NODE METASTASIS; MIDDLE AGED; PATHOLOGY; TREATMENT OUTCOME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, DRUG; ERGOCALCIFEROLS; FEASIBILITY STUDIES; FEMALE; HUMANS; HYPERCALCEMIA; LYMPHATIC METASTASIS; MIDDLE AGED; TAXOIDS; TREATMENT OUTCOME;

EID: 84879186142     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.24350     Document Type: Article

References (26)

1. Coleman RE. Skeletal complications of malignancy. Cancer 1997; 80(Suppl):1588-94; PMID:9362426; http://dx.doi.org/10.1002/(SICI)1097- 0142(19971015)80:8+;1588::AIDCNCR9 3.0.CO;2-G.
2. Goodwin PJ. Vitamin D in cancer patients: above all, do no harm. J Clin Oncol 2009; 27:2117-9; PMID:19349538; http://dx.doi.org/10.1200/JCO.2008.20. 8629.
3. Palmieri C, MacGregor T, Girgis S, Vigushin D. Serum 25-hydroxyvitamin D levels in early and advanced breast cancer. J Clin Pathol 2006; 59:1334-6; PMID:17046848; http://dx.doi.org/10.1136/jcp.2006.042747.
4. Guise TA. Parathyroid hormone-related protein and bone metastases. Cancer 1997; 80(Suppl):1572-80; PMID:9362424; http://dx.doi.org/10.1002/(SICI)1097- 0142(19971015)80:8+;1572::AIDCNCR7 3.0.CO;2-M.
5. Zheng Y, Zhou H, Modzelewski JR, Kalak R, Blair JM, Seibel MJ, et al. Accelerated bone resorption, due to dietary calcium deficiency, promotes breast cancer tumor growth in bone. Cancer Res 2007; 67:9542-8; PMID:17909065; http://dx.doi.org/10.1158/0008-5472.CAN-07-1046.
6. Anzano MA, Smith JM, Uskokovi- MR, Peer CW, Mullen LT, Letterio JJ, et al. 1 alpha,25-Dihydroxy-16-ene-23-yne-26,27-hexafluorocholecalciferol (Ro24-5531), a new deltanoid (vitamin D analogue) for prevention of breast cancer in the rat. Cancer Res 1994; 54:1653-6; PMID:8137276.
7. Colston KW, Pirianov G, Bramm E, Hamberg KJ, Binderup L. Effects of Seocalcitol (EB1089) on nitrosomethyl urea-induced rat mammary tumors. Breast Cancer Res Treat 2003; 80:303-11; PMID:14503802; http://dx.doi.org/10.1023/A: 1024962316691.
8. Koshizuka K, Koike M, Asou H, Cho SK, Stephen T, Rude RK, et al. Combined effect of vitamin D3 analogs and paclitaxel on the growth of MCF-7 breast cancer cells in vivo. Breast Cancer Res Treat 1999; 53:113-20; PMID:10326788; http://dx.doi.org/10.1023/A:1006123819675.
9. El Abdaimi K, Dion N, Papavasiliou V, Cardinal PE, Binderup L, Goltzman D, et al. The vitamin D analogue EB 1089 prevents skeletal metastasis and prolongs survival time in nude mice transplanted with human breast cancer cells. Cancer Res 2000; 60:4412-8; PMID:10969786.
10. Bernardi RJ, Johnson CS, Modzelewski RA, Trump DL. Antiproliferative effects of 1alpha,25-dihydroxyvitamin D(3) and vitamin D analogs on tumor-derived endothelial cells. Endocrinology 2002; 143:2508-14; PMID:12072382; http://dx.doi.org/10.1210/en.143.7.2508.
11. Colston KW, Berger U, Coombes RC. Possible role for vitamin D in controlling breast cancer cell proliferation. Lancet 1989; 1:188-91; PMID:2563099; http://dx.doi.org/10.1016/S0140-6736(89)91204-X.
12. Krishnan AV, Swami S, Feldman D. Vitamin D and breast cancer: inhibition of estrogen synthesis and signaling. J Steroid Biochem Mol Biol 2010; 121:343-8; PMID:20156557; http://dx.doi.org/10.1016/j.jsbmb.2010.02.009.
13. Mantell DJ, Owens PE, Bundred NJ, Mawer EB, Canfield AE. 1 alpha,25-dihydroxyvitamin D(3) inhibits angiogenesis in vitro and in vivo. Circ Res 2000; 87:214-20; PMID:10926872; http://dx.doi.org/10.1161/01.RES.87.3.214.
14. Dawson-Hughes B, Mithal A, Bonjour JP, Boonen S, Burckhardt P, Fuleihan GE, et al. IOF position statement: vitamin D recommendations for older adults. Osteoporos Int 2010; 21:1151-4; PMID:20422154; http://dx.doi.org/10.1007/s00198- 010-1285-3.
15. Holick MF, Binkley NC, Bischoff-Ferrari HA, Gordon CM, Hanley DA, Heaney RP, et al.; Endocrine Society. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2011; 96:1911-30; PMID:21646368; http://dx.doi.org/10.1210/jc. 2011-0385.
16. Vieth R. What is the optimal vitamin D status for health? Prog Biophys Mol Biol 2006; 92:26-32; PMID:16766239; http://dx.doi.org/10.1016/j.pbiomolbio. 2006.02.003.
17. Coyne D, Acharya M, Qiu P, Abboud H, Batlle D, Rosansky S, et al. Paricalcitol capsule for the treatment of secondary hyperparathyroidism in stages 3 and 4 CKD. Am J Kidney Dis 2006; 47:263-76; PMID:16431255; http://dx.doi.org/10.1053/j.ajkd.2005.10.007.
18. Rainville C, Khan Y, Tisman G. Triple negative breast cancer patients presenting with low serum vitamin D levels: a case series. Cases J 2009; 2:8390; PMID:19830074; http://dx.doi.org/10.4076/1757-1626-2-8390.
19. Kennecke H, Yerushalmi R, Woods R, Cheang MC, Voduc D, Speers CH, et al. Metastatic behavior of breast cancer subtypes. J Clin Oncol 2010; 28:3271-7; PMID:20498394; http://dx.doi.org/10.1200/JCO.2009.25.9820.
20. Ferrara N, Hillan KJ, Novotny W. Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy. Biochem Biophys Res Commun 2005; 333:328-35; PMID:15961063; http://dx.doi.org/10.1016/j.bbrc.2005.05.132.
21. Anwikar SR, Bandekar MS, Patel TK, Patel PB, Kshirsagar NA. Tetany: possible adverse effect of bevacizumab. Indian J Cancer 2011; 48:31-3; PMID:21248449; http://dx.doi.org/10.4103/0019-509X.75819.
22. Gnant M, Dubsky P, Hadji P. Bisphosphonates: prevention of bone metastases in breast cancer. Recent Results Cancer Res 2012; 192:65-91; PMID:22307370; http://dx.doi.org/10.1007/978-3-642-21892-7-3.
23. Berruti A, Dogliotti L, Tampellini M, Lipton A, Hirsh V, Saad F, et al. Effect of zoledronic acid (Z) treatment based on serum parathyroid hormone (PTH) levels in patients (pts) with malignant bone disease. ASCO Meeting Abstracts 2006; 24:8610.
24. Amir E, Simmons CE, Freedman OC, Dranitsaris G, Cole DE, Vieth R, et al. A phase 2 trial exploring the effects of high-dose (10,000 IU/day) vitamin D(3) in breast cancer patients with bone metastases. Cancer 2010; 116:284-91; PMID:19918922; http://dx.doi.org/10.1002/cncr.24749.
25. Cheng S, Coyne D. Oral paricalcitol for the treatment of secondary hyperparathyroidism in chronic kidney disease. Ther Clin Risk Manag 2006; 2:297-301; PMID:18360604; http://dx.doi.org/10.2147/tcrm.2006.2.3.297.
26. Schwartz GG, Hall MC, Stindt D, Patton S, Lovato J, Torti FM. Phase I/II study of 19-nor-1alpha-25-dihydroxyvitamin D2 (paricalcitol) in advanced, androgen-insensitive prostate cancer. Clin Cancer Res 2005; 11:8680-5; PMID:16361554; http://dx.doi.org/10.1158/1078-0432.CCR-05-1237.